GLP-1 medications lower the cancer risk of 10 common obesity related cancers for diabetes patients, according to research published in JAMA Network Open on July 5, 2024.In this study, the researchers used electronic health records (EHRs) of 113 million patients of US who were prescribed GLP-1 RAs, insulin, or metformin between 2005 and 2018.Glucagon-like peptide 1 (GLP-1) receptor agonists are more effective to reduce the obesity related cancer risk among type 2 diabetes patients than insulin do...
Learn More